Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Population immunity to pre-Omicron and Omicron SARS-CoV-2 variants in US states and counties through December 1, 2021

View ORCID ProfileFayette Klaassen, View ORCID ProfileMelanie H. Chitwood, View ORCID ProfileTed Cohen, View ORCID ProfileVirginia E. Pitzer, View ORCID ProfileMarcus Russi, View ORCID ProfileNicole A. Swartwood, View ORCID ProfileJoshua A. Salomon, View ORCID ProfileNicolas A. Menzies
doi: https://doi.org/10.1101/2021.12.23.21268272
Fayette Klaassen
1Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Fayette Klaassen
  • For correspondence: fklaassen@hsph.harvard.edu
Melanie H. Chitwood
2Department of Epidemiology of Microbial Diseases and Public Health Modeling Unit, Yale School of Public Health, New Haven, CT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Melanie H. Chitwood
Ted Cohen
2Department of Epidemiology of Microbial Diseases and Public Health Modeling Unit, Yale School of Public Health, New Haven, CT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ted Cohen
Virginia E. Pitzer
2Department of Epidemiology of Microbial Diseases and Public Health Modeling Unit, Yale School of Public Health, New Haven, CT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Virginia E. Pitzer
Marcus Russi
2Department of Epidemiology of Microbial Diseases and Public Health Modeling Unit, Yale School of Public Health, New Haven, CT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Marcus Russi
Nicole A. Swartwood
1Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Nicole A. Swartwood
Joshua A. Salomon
3Department of Health Policy, Stanford University School of Medicine, Stanford, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Joshua A. Salomon
Nicolas A. Menzies
1Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Nicolas A. Menzies
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Prior infection and vaccination both contribute to population-level SARS-CoV-2 immunity. We used a Bayesian model to synthesize evidence and estimate population immunity to prevalent SARS-CoV-2 variants in the United States over the course of the epidemic until December 1, 2021, and how this changed with the introduction of the Omicron variant. We used daily SARS-CoV-2 infection estimates and vaccination coverage data for each US state and county. We estimated relative rates of vaccination conditional on previous infection status using the Census Bureau’s Household Pulse Survey. We used published evidence on natural and vaccine-induced immunity, including waning and immune escape. The estimated percentage of the US population with a history of SARS-CoV-2 infection or vaccination as of December 1, 2021, was 88.2% (95%CrI: 83.6%-93.5%), compared to 24.9% (95%CrI: 18.5%-34.1%) on January 1, 2021. State-level estimates for December 1, 2021, ranged between 76.9% (95%CrI: 67.6%-87.6%, West Virginia) and 94.4% (95%CrI: 91.2%-97.3%, New Mexico). Accounting for waning and immune escape, the effective protection against the Omicron variant on December 1, 2021, was 21.8% (95%CrI: 20.7%-23.4%) nationally and ranged between 14.4% (95%CrI: 13.2%-15.8%, West Virginia), to 26.4% (95%CrI: 25.3%-27.8%, Colorado). Effective protection against severe disease from Omicron was 61.2% (95%CrI: 59.1%-64.0%) nationally and ranged between 53.0% (95%CrI: 47.3%-60.0%, Vermont) and 65.8% (95%CrI: 64.9%-66.7%, Colorado). While over three-quarters of the US population had prior immunological exposure to SARS-CoV-2 via vaccination or infection on December 1, 2021, only a fifth of the population was estimated to have effective protection to infection with the immune-evading Omicron variant.

Significance Both SARS-CoV-2 infection and COVID-19 vaccination contribute to population-level immunity against SARS-CoV-2. This study estimates the immunity and effective protection against future SARS-CoV-2 infection in each US state and county over 2020-2021. The estimated percentage of the US population with a history of SARS-CoV-2 infection or vaccination as of December 1, 2021, was 88.2% (95%CrI: 83.6%-93.5%). Accounting for waning and immune escape, protection against the Omicron variant was 21.8% (95%CrI: 20.7%-23.4%). Protection against infection with the Omicron variant ranged between 14.4% (95%CrI: 13.2%-15.8%%, West Virginia) and 26.4% (95%CrI: 25.3%-27.8%, Colorado) across US states. The introduction of the immune-evading Omicron variant resulted in an effective absolute increase of approximately 30 percentage points in the fraction of the population susceptible to infection.

Competing Interest Statement

VEP has received reimbursement from Merck and Pfizer for travel expenses to Scientific Input Engagements unrelated to the topic of this manuscript. All other authors have declared that no competing interest exist.

Funding Statement

VEP reports grants from National Institute of Allergy and Infectious Diseases R01 AI137093 TC reports grants from National Institute of Allergy and Infectious Diseases R01 AI112438 NAM reports grants from National Institute of Allergy and Infectious Diseases R01 AI146555-01A1, the Centers for Disease Control and Prevention though the Council of State and Territorial Epidemiologists (NU38OT000297-03), and the Centers for Disease Control and Prevention (75D30121F0003). JAS reports funding from the Centers for Disease Control and Prevention though the Council of State and Territorial Epidemiologists (NU38OT000297-02) and the National Institute on Drug Abuse (3R37DA01561217S1). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

All data used in the main analysis are available from The Covid Tracking Project, Johns Hopkins CSSE, Github, US Census Bureau, Ipsos and a JAMA publication. Code for analyses is available from GitHub.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Competing interest statement: VEP has received reimbursement from Merck and Pfizer for travel expenses to Scientific Input Engagements unrelated to the topic of this manuscript. All other authors have declared that no competing interest exist.

  • Funding updated. Minor textual revisions.

Data Availability

All data used in the main analysis are available from The Covid Tracking Project, Johns Hopkins CSSE, Github, US Census Bureau, Ipsos and a JAMA publication. Code for analyses is available from GitHub. https://covidtracking.com/ https://www.mass.gov/info-details/covid-19-response-reporting https://www.openicpsr.org/openicpsr/project/144903/version/V1/view https://github.com/bansallab/vaccinetracking/tree/main/vacc_data https://www.census.gov/programs-surveys/household-pulse-survey/data.html https://github.com/covidestim/covidestim/immunity-waning https://jamanetwork.com/journals/jama/fullarticle/2784013

https://covidtracking.com/

https://www.mass.gov/info-details/covid-19-response-reporting

https://www.openicpsr.org/openicpsr/project/144903/version/V1/view

https://github.com/bansallab/vaccinetracking/tree/main/vacc_data

https://www.census.gov/programs-surveys/household-pulse-survey/data.html

https://github.com/covidestim/covidestim/immunity-waning

https://jamanetwork.com/journals/jama/fullarticle/2784013

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Back to top
PreviousNext
Posted March 01, 2022.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Population immunity to pre-Omicron and Omicron SARS-CoV-2 variants in US states and counties through December 1, 2021
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Population immunity to pre-Omicron and Omicron SARS-CoV-2 variants in US states and counties through December 1, 2021
Fayette Klaassen, Melanie H. Chitwood, Ted Cohen, Virginia E. Pitzer, Marcus Russi, Nicole A. Swartwood, Joshua A. Salomon, Nicolas A. Menzies
medRxiv 2021.12.23.21268272; doi: https://doi.org/10.1101/2021.12.23.21268272
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Population immunity to pre-Omicron and Omicron SARS-CoV-2 variants in US states and counties through December 1, 2021
Fayette Klaassen, Melanie H. Chitwood, Ted Cohen, Virginia E. Pitzer, Marcus Russi, Nicole A. Swartwood, Joshua A. Salomon, Nicolas A. Menzies
medRxiv 2021.12.23.21268272; doi: https://doi.org/10.1101/2021.12.23.21268272

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (175)
  • Allergy and Immunology (421)
  • Anesthesia (97)
  • Cardiovascular Medicine (901)
  • Dentistry and Oral Medicine (170)
  • Dermatology (102)
  • Emergency Medicine (257)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (407)
  • Epidemiology (8793)
  • Forensic Medicine (4)
  • Gastroenterology (405)
  • Genetic and Genomic Medicine (1864)
  • Geriatric Medicine (179)
  • Health Economics (388)
  • Health Informatics (1292)
  • Health Policy (644)
  • Health Systems and Quality Improvement (493)
  • Hematology (207)
  • HIV/AIDS (395)
  • Infectious Diseases (except HIV/AIDS) (10574)
  • Intensive Care and Critical Care Medicine (564)
  • Medical Education (193)
  • Medical Ethics (52)
  • Nephrology (218)
  • Neurology (1760)
  • Nursing (104)
  • Nutrition (267)
  • Obstetrics and Gynecology (343)
  • Occupational and Environmental Health (461)
  • Oncology (966)
  • Ophthalmology (283)
  • Orthopedics (107)
  • Otolaryngology (177)
  • Pain Medicine (118)
  • Palliative Medicine (43)
  • Pathology (264)
  • Pediatrics (557)
  • Pharmacology and Therapeutics (266)
  • Primary Care Research (221)
  • Psychiatry and Clinical Psychology (1846)
  • Public and Global Health (3991)
  • Radiology and Imaging (655)
  • Rehabilitation Medicine and Physical Therapy (344)
  • Respiratory Medicine (536)
  • Rheumatology (216)
  • Sexual and Reproductive Health (178)
  • Sports Medicine (166)
  • Surgery (197)
  • Toxicology (37)
  • Transplantation (107)
  • Urology (80)